Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

40%

2 trials in Phase 3/4

Results Transparency

40%

2 of 5 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

Phase 1

3(60.0%)

Phase 3

2(40.0%)

5Total

Phase 1(3)

Phase 3(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials

NCT05046795Phase 3Completed

Revefenacin in Chinese Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease(COPD)

Role: lead

NCT05207111Phase 1Completed

Fasting Bioavailability Study of Mylan's Revefenacin Inhalation Solution

Role: lead

NCT02215122Phase 1Completed

Bioequivalence Study to Assess Systemic Exposure of FP and SAL FDC From Different DPIs

Role: lead

NCT02474017Phase 1Completed

An Open Study to Assess the Robustness of the CRC749 Inhaler

Role: lead

NCT02245672Phase 3Completed

MGR001 / Advair Diskus Local Equivalence Study in Asthma

Role: lead

All 5 trials loaded